Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents.
BACKGROUND
Combination antifungal/corticosteroid preparations are widely used by nondermatologists in the treatment of superficial fungal infections in patients of all ages. Over half of the prescriptions written for the most commonly used combination agent clotrimazole 1%/betamethasone diproprionate 0.05% cream (Lotrisone, Schering, Kenilworth, NJ) were prescribed for children younger than 4 years old. Our pediatric dermatology division has recently encountered a series of children with recurrent or persistent tinea corporis, especially tinea faciei, treated initially with combination antifungal/corticosteroid cream.


METHODS
All children evaluated for tinea corporis in a university hospital pediatric dermatology clinic from January through June 2001 were identified from the clinic registry for a retrospective chart review. Response to therapy was confirmed by telephone survey and/or follow-up visits at least 1 month after clearing of infection.


RESULTS
Six children ranging in age from 4 to 11 years were evaluated for tinea corporis in a pediatric dermatology clinic at our institution during the 6-month period. All 6 children were diagnosed clinically by their pediatrician with tinea corporis and initially treated with clotrimazole 1%/betamethasone diproprionate 0.05% cream for 2 to 12 months. In our pediatric dermatology clinic, patients had their diagnosis confirmed with a positive potassium hydroxide preparation and were treated with one of several oral or topical antifungal agents with clearing of all tinea infections.


CONCLUSIONS
The use of combination clotrimazole 1% cream/betamethasone diproprionate 0.05% cream (Lotrisone) for the treatment of tinea corporis may be associated with persistent/recurrent infection.
Alston
Sharonda J
SJ
Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Cohen
Bernard A
BA
Braun
Marisa
M
D000287:Administration, Topical; D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D003022:Clotrimazole / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005938:Glucocorticoids; D006801:Humans; D007223:Infant; D012008:Recurrence; D012189:Retrospective Studies; D014005:Tinea / Q000188:drug therapy*; D017211:Treatment Failure
D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D005938:Glucocorticoids; D000499:Allylamine; C029178:naftifine; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D003022:Clotrimazole